Pelvital

Executive Summary

Pelvital is a Minneapolis-based medical device and digital health company addressing the underserved market of pelvic floor disorders. Its flagship product, Flyte, is an FDA-cleared, at-home intravaginal device that delivers mechanotherapy for stress urinary incontinence (SUI) in women. Unlike traditional treatments such as surgery or pelvic floor exercises, Flyte offers a non-invasive, convenient solution that empowers patients to manage their condition independently. The company targets a large and growing demographic: over 30 million women in the US alone suffer from SUI, yet many delay or avoid treatment due to embarrassment or lack of effective home-based options. Flyte’s clearance differentiates it in a market dominated by pessaries, electrical stimulation devices, and prescription drugs, positioning Pelvital to capture share through direct-to-consumer channels and partnerships with urogynecologists. Although Pelvital remains private and has not disclosed funding or revenue, its FDA clearance and focus on a high-need condition suggest near-term commercialization potential. Key challenges include building brand awareness, securing reimbursement, and competing with established pelvic health products. However, the company’s digital health component may enable remote monitoring and data collection, offering a path to value-based care. With a lean team and a clear regulatory pathway, Pelvital appears poised for growth, though execution risk remains until clinical adoption and patient outcomes are demonstrated at scale.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round Announcement65% success
• Q4 2026Clinical Study Results for Overactive Bladder (OAB) Indication40% success
• 2027Reimbursement Code Assignment from CMS or Private Payer30% success